Low-Sodium Oxybate

How it works

Dosage & preparation

Preparation

Interactions

Comparisons

Highlighted claims

• The trial uses XYWAV, an oral oxybate solution with lower sodium content than sodium oxybate. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Participants take low-sodium oxybate immediately before sleep because oxybate has a short half-life of about 30 to 60 minutes. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The starting dose is 2 g at bedtime and is titrated weekly toward a 5 g target dose after 6 weeks. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Low-sodium oxybate was chosen over sodium oxybate because it reduces sodium intake by 92%. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Valproic acid, phenytoin, ethosuximide, and topiramate may interact with low-sodium oxybate. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Low-sodium oxybate is intended to deepen slow-wave sleep and thereby potentially stimulate glymphatic clearance. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial